Improved analysis HPLC-ESI/triple method for mapping the methotrexate by mass spectrometry

Area of Science:

• Pharmacology
• Analytical Chemistry
• Pediatric Oncology

Background:

• Methotrexate is crucial in pediatric cancer treatment.
• Interindividual variability in methotrexate clearance causes toxicity.
• Sensitive analytical methods are vital for patient safety.

Purpose of the Study:

• Establish a sensitive HPLC-ESI/triple method for quantifying plasma methotrexate.
• Facilitate therapeutic drug monitoring in pediatric patients.
• Understand methotrexate pharmacokinetics in vivo.

Main Methods:

• Developed and validated a high-performance liquid chromatography-tandem mass spectrometry (HPLC-ESI/triple) method.
• Quantified methotrexate concentrations in pediatric plasma samples.
• Analyzed factors influencing methotrexate blood concentration.

Main Results:

• The HPLC-ESI/triple method accurately and sensitively quantifies methotrexate in 10 μL plasma.
• Recovery rates exceeded 90% with minimal matrix effects.
• Patient age significantly influences methotrexate concentration; older children had lower levels.
• Monitoring within 24 hours post-administration is recommended.

Conclusions:

• A robust HPLC-ESI/triple method for methotrexate plasma quantification was established.
• The method enables precise therapeutic drug monitoring in pediatric oncology.
• Findings support optimized methotrexate dosing and improved patient outcomes.